Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Prilosec

Executive Summary

Company confirmed in a Jan. 11 release that it has received an "approvable" letter from FDA covering expanded use of the anti- ulcer drug Prilosec (omeprazole) and that Merck "is in discussion with the agency as to the extent of the new claims." Merck was notified by FDA Dec. 26 that Prilosec is approvable for short-term treatment of active duodenal ulcers poorly responsive to customary medical treatment ("The Pink Sheet" Jan. 7, "In Brief"). Merck said in the release that the approvable letter from FDA "contained an expanded indication that is narrower than that originally recommended in May 1990 by an FDA advisory committee. Merck has not accepted the narrower version and is discussing final language with FDA. Rumors emanating from Europe about Merck withdrawing the application are totally unfounded." Prilosec is approved in the U.S. for treatment of Zollinger-Ellison syndrome and gastroesophageal reflux disease.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel